Last updated on November 2018

Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Promyelocytic Leukemia With PML-RARA | Chromosomal translocation | Time
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Confirmed to have a diagnosis of APL, which is defined as:
  • Positive t(15:17) by fluorescence in situ hybridization (FISH) or conventional karyotype
  • Positive promyelocytic leukemia/retinoic acid receptor PML/RAR alpha by polymerase chain reaction (PCR)
  • Patients must accept treatment and supportive care guidelines
  • Referrals must be made as early as possible but no later than 5 calendar days after ATRA therapy is initiated; consent can be obtained up till day 7 or earlier
  • Co-management can be started as soon as referral is made including weekends; the physician at the outlying facility should make every effort to call the APL expert at the first suspicion of APL

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.